<DOC>
	<DOCNO>NCT00005906</DOCNO>
	<brief_summary>Lymphangioleiomyomatosis ( LAM ) , disease primarily woman child-bearing age , characterize cystic lung disease abdominal tumor ( e.g. , angiomyolipomas ) . Within LAM patient population subset patient develop chylous effusion lymphangioleiomyomas . Treatment many symptom ineffective . Previous study somatostatin octreotide clinical setting show reduction chylous effusion . This study assess effectiveness octreotide symptomatic patient LAM , lymphangioleiomyomas and/or chylous effusions/ascites , peripheral lymphedema chyluria .</brief_summary>
	<brief_title>Treatment With Octreotide Patients With Lymphangioleiomyomatosis</brief_title>
	<detailed_description>Lymphangioleiomyomatosis ( LAM ) , disease primarily woman child-bearing age , characterize cystic lung disease abdominal tumor ( e.g. , angiomyolipomas ) . Within LAM patient population subset patient develop chylous ascites , chylous pleural effusion , chyluria , peripheral lymphedema , and/or lymphangioleiomyomas . Lymphangioleiomyomas believe result proliferation abnormal smooth muscle cell within lymphatic system , appear obstruct fluid outflow , lead fluid accumulation increase size . The lymphangioleiomyomas may occur anywhere along axial lymphatic chain . In patient LAM , occur frequently thorax , abdomen pelvis may give rise myriad symptom ( e.g. , paresthesia , palpitation , peripheral edema ) . In patient , treatment many symptom , i.e. , elevation low extremity , paracentesis , thoracentesis , diuretic , and/or surgery , ineffective . Previous study somatostatin octreotide clinical setting ( e.g. , traumatic damage lymphatics ) show successful reduction chylous effusion , chyluria , ascites , peripheral lymphedema , therapy less effective . This study ass effectiveness octreotide symptomatic patient LAM , lymphangioleiomyomas and/or chylous effusions/ascites , peripheral lymphedema chyluria . The dose octreotide start 50 microgram ( ug ) subcutaneous route twice day . After two week dose increase 200 ug per day two week later 400 ug/day . Maximal dose 400 ug twice day .</detailed_description>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Lymphangioleiomyomatosis</mesh_term>
	<mesh_term>Lymphangiomyoma</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients enrol lymphangioleiomyomatosis natural history protocol symptom associate one following : 1. lymphangioleiomyomas 2. chylous pleural effusion 3. peripheral lymphedema 4. chyloptysis 5. proteinlosing enteropathy 6. chyluria Patients include protocol symptom attribute process . Patients malabsorption disorder , diabetes , hypo/hyperthyroidism , endocrinerelated disorder include justified clinically base severity symptom . EXCLUSION CRITERIA : 1 . Hypersensitivity somatostatin , octreotide analogues 2 . Patients hepatitis B , hepatitis C , clinically significant liver diseases 3 . Transplant patient 4 . Pregnant woman woman beastfeeding 5 . Patient another responsible party unable give subcutaneous injection 6 . Patient unwilling follow per guideline set forth 7 . Patients decrease renal function ( creatinine great 1.5 ) 8 . Patients HIV infection 9 . Immunosuppressed patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Chylous Ascites</keyword>
	<keyword>Chylous Pleural Effusion</keyword>
	<keyword>Inhibitory Effects</keyword>
	<keyword>Lymphangioleiomyoma</keyword>
	<keyword>Somatostatin</keyword>
	<keyword>Lymphangioleiomyomatosis ( LAM )</keyword>
</DOC>